Chronic allograft nephropathy: A multiple approach to target nonimmunological factors

Contributions to Nephrology

Volumn 146, Issue , 2005, Pages 87-94

  Ruggenenti, Piero ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRANSPLANTATION; ANIMAL; CHRONIC DISEASE; COMPARATIVE STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; MALE; METHODOLOGY; NEPHRON; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT;

ANIMALS; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; NEPHRONS; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; TRANSPLANTATION, HOMOLOGOUS;

EID: 16544380064     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (38)

1. Terasaki P, Yuge J, Cecka JM, Gjertson DW, et al: Thirty-year trends in clinical kidney transplantation; in Terasaki P, Cecka JM (eds): Clinical Transplants 1993. Los Angeles, UCLA Tissue Typing Laboratory, 1994, pp 553-562.
2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, et al: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605-612.
3. Paul L: Chronic renal transplant loss. Kidney Int 1995;47:1491-1499.
4. Hayry P, Isoniemi H, Ylmaz S, Mennander A, et al: Chronic allograft rejection. Immunol Rev 1993;134:33-79.
5. Paul LC, Benediktsson H: Chronic transplant rejection: Magnitude of the problem and pathogenic mechanisms. Transplant Rev 1993;134:5-19.
6. Perico N, Remuzzi G: Angiotensin II receptor antagonists and treatment of hypertension and renal disease. Curr Opin Nephrol Hypertens 1998;7:571-578.
7. Taal MW, Brenner BM: Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 2000;57:1803-1817.
8. Remuzzi G, Perico N: Protecting single-kidney allografts from long-term functional deterioration. J Am Soc Nephrol 1998;9:1321-1332.
9. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-1456.
10. Curtis JJ, Luke RG, Whelchel JD, Diethelm AG, et al: Inhibition of angiotensin-converting enzyme in renal transplant recipients with hypertension. N Engl J Med 1983;308:377-381.
11. Ahmad T, Coulthard MG, Eastham EJ: Reversible renal failure due to the use of captopril in a renal allograft recipient treated with cyclosporin. Nephrol Dial Transplant 1989;4:311-312.
12. Solez K, Axelsen RA, Benediktsson H, Burdick JF, et al: International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993;44:411-422.
13. Mackenzie HS, Brennner BM: Antigen-independent determinants of late renal allograft outcome: The role of renal mass. Curr Opin Nephrol Hypertens 1996;5:289-296.
14. Brenner BM, Cohen RA, Milford EL: In renal transplantation, one size may not fit all. J Am Soc Nephrol 1992;3:162-169.
15. Brenner BM: Hemodynamically mediated glomerular injury and the progressive nature of glomerular disease. Kidney Int 1983;23:647-655.
16. Remuzzi G: Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury. Curr Opin Nephrol Hypertens 1995;4:339-342.
17. Ruggenenti P, Remuzzi G: Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease. Curr Opin Nephrol Hypertens 1997;6:489-495.
18. Mackenzie HS, Ziai F, Nagano H, Azuma H, et al: Candesartan cilexetil reduces chronic renal allograft injury in Fisher - Lewis rats. J Hypertens 1997;15(suppl 4):S21-S25.
19. Benediktsson H, Chea R, Davidoff A, Paul LC: Antihypertensive drug treatment in chronic renal allograft rejection in the rat. Effect on structure and function. Transplantation 1996;62:1634-1642.
20. Amuchastegui SC, Azzollini N, Mister M, Pezzotta A, et al: Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 1998;9:1948-1955.
21. Ziai F, Nagano H, Kusaka M, Coito AJ, et al: Renal allograft protection with losartan in Fisher - Lewis rats: Hemodynamics, macrophages, and cytokines. Kidney Int 2000;57:2618-2625.
22. Bochicchio T, Sandoval G, Ron O, Perez-Grovas H, et al: Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Kidney Int 1990;38:873-879.
23. Rell K, Linde J, Morzycka-Michalik M, Gaciong Z, et al: Effect of enalapril on proteinuria after kidney transplantation. Transpl Int 1993;6:213-217.
24. Mulhern J, Lipkowitz GS, Braden GL, Madden RL, et al: Association of post-renal transplant erythrocytosis and microalbuminuria: Response to angiotensin-converting enzyme inhibition. Am J Nephrol 1995;15:318-322.
25. Oppenheimer F, Flores R, Cofan F, Campistol JM, et al: Treatment with angiotensin-converting enzyme inhibitors in renal transplantation with proteinuria. Transplant Proc 1995;27:2235-2236.
26. Oka K, Imai E, Moriyama T, Akagi Y, et al: A clinicopathological study of IgA nephropathy in renal transplant recipients: Beneficial effect of angiotensin-converting enzyme inhibitor. Nephrol Dial Transplant 2000;15:689-695.
27. Mourad G, Ribstein J, Mimran A: Converting-enzyme inhibitor versus calcium antagonist in cyclosporin-treated renal transplants. Kidney Int 1993;43:419-425.
28. Van der Schaaf MR, Hene RJ, Floor M, Blankestijn PJ, et al: Hypertension after renal transplantation: Calcium channel or converting enzyme blockade? Hypertension 1995;25:77-81.
29. Grekas D, Dioudis C, Kalevrosoglou I, Alivanis P, et al: Renal hemodynamics in hypertensive renal allograft recipients: Effects of calcium antagonists and ACE inhibitors. Kidney Int 1996;49 (suppl 55):S97-S100.
30. Navarro JF, MAcia ML, Garcia J: Control of severe proteinuria with losartan after renal transplantation. Am J Nephrol 1998;18:261-262.
31. Del Castillo D, Campistol JM, Guirado L, Capdevilla L, et al: Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 1998;54(suppl 68): S135-S139.
32. Campistol JM, Inigo P, Jimenez W, Lario S, et al: Losartan decreases plasma levels of TGF-b1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999;56:714-719.
33. Stigant CE, Cohen J, Vivera M, Zaltzman JS: ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy. Am J Kidney Dis 2000;35:58-63.
34. Calvino J, Lens XM, Romero R, Sanchez-Guisande D: Long-term anti proteinuric effect of Losartan in renal transplant recipients treated for hypertension. Nephrol Dial Transplant 2000;15:82-86.
35. Border WA, Noble NA: Transforming growth factor-b in tissue fibrosis. N Engl J Med 1994;51:646-671.
36. Border WA, Noble NA: Interactions of transforming growth factor-b and angiotensin II in renal fibrosis. Hypertension 1998;31:181-188.
37. Kannel WB, Stampfer MJ, Castelli WP, Verter J: The prognostic significance of proteinuria: The Framingham study. Am Heart J 1984;108:1347-1352.
38. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, et al: Long-term survival in renal transplant recipients with graft function. Kidney Int 2000;57:307-313.